Drug Manufacturers – Major
(ABT) Earnings Season in Full Swing – Earnings Preview
Earnings Preview 1/20/12 Earnings season will be in full swing this week. 422 firms are scheduled to report, and 117 of those will be members of the S&P 500. By the end of the week we should have a very good handle on just how weak or strong this earnings season will be. The...
24Jan2012 | vitalstocks | 0 comments | Continued(JNJ) Mixed Earnings, Greece May Slip Markets
With nothing major on the domestic economic calendar, headlines about Greece’s as-yet unsuccessful negotiations with its bondholders to restructure its private debt may get some traction. But today’s market action will be mostly about the slew of mixed earnings reports from...
24Jan2012 | vitalstocks | 0 comments | Continued(JNJ) Jan 24: Day of Earnings! – Economic Highlights
With nothing major on the domestic economic calendar, headlines about Greece’s as-yet unsuccessful negotiations with its bondholders to restructure its private debt may get some traction. But today’s market action will be mostly about the slew of mixed earnings reports from...
24Jan2012 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb Company Kicks Off 2012 Pharma Deals
The spate of acquisitions in the pharma industry continues in 2012 with Bristol-Myers Squibb Company (BMY) announcing the first major deal of the new year. Major merger and acquisition (M&A) deals have taken place in the pharma sector over the last couple of years. With most...
9Jan2012 | vitalstocks | 0 comments | Continued(BMY) Company News for January 04, 2012 – Corporate Summary
• Share prices of natural gas producer Devon Energy Corp (NYSE:DVN) gained 6.63% after the company announced it would sell a stake in five of its exploratory projects across the U.S., to Sinopec International Petroleum Exploration & Production, a unit of China Petroleum...
8Jan2012 | vitalstocks | 0 comments | Continued(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant...
29Dec2011 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb Sees Pipeline Setback
Bristol-Myers Squibb Company (BMY) recently suffered a pipeline setback with its oncology candidate, brivanib, performing disappointingly in a late-stage study (BRISK-PS). The study evaluated brivanib as a combination therapy in liver cancer patients who had either failed or...
24Dec2011 | vitalstocks | 0 comments | Continued(NVS) Novartis’ Cancer Drug Afinitor Shows Promise for Breast Cancer
Novartis’ (NVS) cancer drug Afinitor took a significant step forward, as the company once again presented encouraging data from late-stage trials of Afinitor for the treatment of breast cancer, an indication for which management estimates sales potential in excess of $1 billion....
12Dec2011 | vitalstocks | 0 comments | Continued(AZN) AstraZeneca Drug Cleared by the European Commission
AstraZeneca (AZN) and its partner Bristol-Myers Squibb (BMY) announced recently that Komboglyze has been approved by the European Commission (EC) in European Union (EU). Komboglyze is a combination of Onglyza (saxagliptin), a DPP-4 inhibitor and metformin, a generic drug for...
8Dec2011 | vitalstocks | 0 comments | Continued(JNJ) Spotlight on Hepatitis-C Market
Is the hepatitis-C market the next Mecca for the pharma/biotech sector? It seems so if we go by the flurry of activity and heightened interest in this market in the past few quarters. The hepatitis-C virus (HCV) market seems to have caught the eye of several pharma/biotech companies...
7Dec2011 | vitalstocks | 0 comments | Continued(PFE) Watson Pharmaceuticals Joins Pfizer for Generic Lipitor
November 30, 2011 was a big day for Pfizer, Inc. (PFE) with its blockbuster cholesterol drug, Lipitor, losing exclusivity in the US. With so many drugs losing exclusivity, why is the loss of exclusivity of Lipitor such a major event? Well, Lipitor has been a huge revenue generator...
6Dec2011 | vitalstocks | 0 comments | Continued(NVS) Novartis’ Rasitrio Cleared in European Union
Novartis (NVS) recently announced that its triple combination hypertension pill Rasitrio has been cleared in the European Union (EU). Rasitrio combines the currently marketed hypertension pill Razilez (marketed as Tekturna in the US) with amlodipine and hydrochlorothiazide (HCT)....
28Nov2011 | vitalstocks | 0 comments | Continued(JNJ) Bayer Cut to Underperform
We recently downgraded Bayer (BAYRY) to Underperform from Neutral purely on valuation grounds. We believe that the stock is overvalued at current levels. Even though the US Food and Drug Administration (FDA) cleared Bayer/ Johnson & Johnson’s (JNJ) potential blockbuster...
23Nov2011 | vitalstocks | 0 comments | Continued(JNJ) Johnson & Johnson 2011 Third Quarter Earnings Scorecard
Following the release of third quarter 2011 results, majority of the analysts covering Johnson & Johnson (JNJ) revised their earnings estimates. While 2011 estimates have been revised in both directions, 2012 estimates have gone predominantly downwards. Third Quarter Recap Johnson...
6Nov2011 | vitalstocks | 0 comments | Continued(MRK) Merck Drug Candidate Presents New Data
Merck (MRK) recently presented new clinical and pre-clinical data on its phase III pipeline candidate, odanacatib. Odanacatib is an investigational cathepsin K (cat-K) inhibitor which is being developed for the treatment of osteoporosis in post-menopausal women. Results were...
21Sep2011 | vitalstocks | 0 comments | Continued(AZN) AstraZeneca Coverage Initiated at Neutral
We are initiating coverage on AstraZeneca (AZN) with a Neutral recommendation and a target price of $47.00. AstraZeneca, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world. AstraZeneca’s business can be broken down into separate lines...
21Sep2011 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb Presents HCV Data
Recently, Bristol-Myers Squibb Company (BMY) presented encouraging data from a phase II study (n=48) which evaluated its candidate BMS-790052 in combination with peginterferon and ribavirin (standards of care) for treating patients suffering from the hepatitis C virus (HCV)....
20Sep2011 | vitalstocks | 0 comments | Continued(NVS) Novartis Drug Cleared in European Union for SEGA
Novartis (NVS) recently received a boost when its drug Votubia was approved for the treatment of subependymal giant cell astrocytomas (SEGA), a benign brain tumor associated with tuberous sclerosis (TS) in the European Union (EU). For the first time ever will such a medication...
20Sep2011 | vitalstocks | 0 comments | Continued(AZN) AstraZeneca’s Brilinta Now in US
AstraZeneca plc (AZN) recently announced the US launch of Brilinta (ticagrelor). The drug was approved by the US Food and Drug Administration (FDA) last month, to reduce the rate of heart attack and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS). Following...
15Sep2011 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb and Pfizer Get Encouraging Data
Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer (PFE) announced encouraging data from a late-stage study (ARISTOTLE: n=18,201) which evaluated their blood thinner Eliquis (apixaban) in patients suffering from erratic heartbeat and carrying at least one additional...
14Sep2011 | vitalstocks | 0 comments | Continued(NVS) Novartis Neuroendocrine Tumors Drug Cleared in European Union
Novartis’(NVS) drug Afinitor was recently approved in the European Union (EU) for the treatment of patients with advanced neuroendocrine tumors (NET) of pancreatic origin with progressive disease. The drug is already approved in the US for the indication. The approval was based...
11Sep2011 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb Company Reports Solid Quarter
Bristol-Myers Squibb Company’s (BMY) second quarter 2011 earnings (excluding special items) of $0.56 per share surpassed the Zacks Consensus Estimate by $0.01and the year-ago earnings by $0.02. Higher revenues boosted earnings in the reported quarter. On a reported basis (including...
3Aug2011 | vitalstocks | 0 comments | Continued(ABT) Stock Market News for August 2, 2011 – Market News
The benchmarks’ roller-coaster ride finally came to a stop with markets losing modest points, as manufacturing data spoiled the party after Obama and congressional leaders confirmed they had reached an agreement on the debt ceiling. Investor mood swayed from positive to cautious...
2Aug2011 | vitalstocks | 0 comments | Continued(NVS) Novartis Presents Afinitor Data
Recently, Novartis (NVS) presented data from a late-stage study (EXIST-1) of its cancer drug Afinitor (everolimus). The randomized, placebo-controlled, double-blind, multicenter study evaluated the safety and effectiveness of the drug compared to placebo for treating patients...
12Jul2011 | vitalstocks | 0 comments | Continued(NVS) Novartis AG’s Lung Drug Cleared in US
Novartis AG (NVS) recently announced that its once-daily long-acting beta2-agonist (LABA) Arcapta Neohaler (75 mcg) was cleared by the US Food and Drug Administration (FDA) for the long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic...
11Jul2011 | vitalstocks | 0 comments | Continued(MRK) Japanese Approval for Merck Products
Merck (MRK) recently announced that it received approval for three products in Japan. The Japanese Ministry of Health, Labour and Welfare (MHLW) approved Gardasil [human papillomavirus quadrivalent (Types 6, 11, 16 and 18) vaccine, recombinant], Zolinza (vorinostat) and Cubicin...
11Jul2011 | vitalstocks | 0 comments | Continued(NVS) Novartis AG’s Afinitor Impresses Again
It seems Novartis AG’s (NVS) breast cancer drug, Afinitor (everolimus), is getting into a habit of delivering positive news. Right after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Afinitor last week...
7Jul2011 | vitalstocks | 0 comments | Continued(JNJ) Boost for Bayer and Johnson & Johnson
Recently, the US Food and Drug Administration (FDA) delivered a huge boost for Bayer (BAYRY) and partner Johnson & Johnson (JNJ) by clearing their blood-thinner (anticoagulant) Xarelto (rivaroxaban). The US regulatory body cleared the drug, which has blockbuster potential,...
5Jul2011 | vitalstocks | 0 comments | Continued(LLY) Eli Lilly Provides Research and Development Update
Eli Lilly and Company (LLY) recently provided an insight into its research and development (R&D) plans and mid-term guidance at a meeting with the investment community. The company outlined its plans for combating the impact of the patent expiration of several key products....
5Jul2011 | vitalstocks | 0 comments | Continued(JNJ) Johnson & Johnson Recalls Tylenol Lot
Johnson & Johnson (JNJ) recently announced that it is recalling one lot of Tylenol Extra Strength Caplets, 225 count bottles, at the retail level. The lot, manufactured in Feb 2009, is being recalled in the US. The recall was initiated due to reports regarding odor including...
30Jun2011 | vitalstocks | 0 comments | Continued